Recurrent Malignant Pericardial Effusion Management: The Pericardio-Peritoneal Window Antonio Mazzella, Giovanni Caffarena, Claudia Bardoni, Giuseppe Nicolosi, Patrick Maisonneuve, et al. Journal of Clinical Medicine, 2026 Introduction: Malignant pericardial effusion (MPE) represents a relatively rare complication in various types of solid tumors. Its management is often challenging. One solution can be represented by surgical approaches, including a pericardio-peritoneal window (PPW), which allows draining the fluid into the abdominal cavity. The aim of this study is to investigate the efficacy and long-term outcomes of the PPW procedure as a definitive therapeutic strategy for MPE. Materials and methods: We retrospectively and prospectively observed pre-, peri-, and postoperative data of patients undergoing pericardio-peritoneal window creation from 2010 to December 2023 at the European Institute of Oncology (IEO), including the surgical procedures needed, total and specific postoperative complications, 30-day mortality rate, relapse rate, and the treatment of possible relapses. Results: A total of 44 consecutive patients underwent a pericardio-peritoneal window. In 28 patients (63.8%) PPW was associated with mono or bilateral videothoracoscopy for pleural biopsies/talc poudrage. In 23 cases, pre-operative percutaneous pericardial drainage (usually 1–2 days before surgery) was performed. No intraoperative deaths were observed. The 30-day mortality was 9% (four patients). We observed pericardial effusion recurrence in three patients at two months and in five patients at six months. In only two cases we treated this condition because of a pre-tamponade condition, treated by percutaneous pericardial drainage. The success rate of the PPW regarding pericardial relapse requiring further procedures was 95.5%. Conclusions: Patients presenting with a favorable short-term prognosis benefit from the pericardio-peritoneal window as a safe and effective method for resolving malignant pericardial effusion. Conversely, pericardial drainage is recommended as the most appropriate therapy for those with a less favorable prognosis.
Diagnostic Performance and Cell Count of EBUS–TBNA Needle Gauges: A Prospective Trial Juliana Guarize, Cristina Diotti, Monica Casiraghi, Stefano Donghi, Clementina Di Tonno, et al. Journal of Clinical Medicine, 2023 Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a well-established diagnostic procedure for evaluating hilar and mediastinal lymphadenopathies and is the gold standard for lung cancer diagnosis and staging. Recent studies assessed the effectiveness of the 19-G flex needle in obtaining larger EBUS-TBNA samples, and prospective small series gave similar results in terms of diagnostic yield when testing different gauge needles. The lack of homogeneity between series and the small sample size of some prospective cohorts poses a limit to the validity of those results. This prospective controlled study compared the 19-G flex and 22-G needles in terms of diagnostic yield. An objective laboratory method was used to count cells and compare the two needles’ cytologic yields. Material. A prospective controlled study was conducted on 90 patients undergoing EBUS-TBNA for the diagnosis of hilar and mediastinal lymphadenopathies. The institutional ethic committee (IEO573) approved the study, and informed consent was obtained from all patients. Results. A total of 90 patients were enrolled in this study, 84.4% of whom were diagnosed with malignancy and 15.6% with non-neoplastic disease. Sensitivity for malignancy was 93.4% (CI: 87.4–97.1%) for the 19-G needle and 92.6% (CI: 86.3–96.5%) for the 22-G needle (p = 0.80). The percentage of malignant cells in the cell block was 63.9% and 61.5% for the 22-G and 19-G needles, respectively. The cell count assessed by flow cytometry was 2071 cells/µL (IQR: 600,2265) with the 22-G needle and 2761 cells/µL (IQR: 505,3250) with the 19-G needle (p = 0.79). The malignant cell count was 0.05 × 103 cells/µL with the 22-G and 0.08 × 103 cells/µL with the 19-G needle (p = 0.70). There was no difference in the presence of tissue cores in the samples, and rapid on-site evaluation (ROSE) cellularity was comparable between the two needles. Conclusions. The 19-G flex EBUS-TBNA needle is comparable to the 22-G needle in terms of diagnostic yield for cyto-histological evaluation of hilar and mediastinal lymphadenopathies. There is no difference between the 19-G and 22-G needle cell counts evaluated by flow cytometry.
The Role of Surgery in Primary Chest Wall Tumors: Over 20 Years’ Experience in Resection and Reconstruction Giorgio Lo Iacono, Antonio Mazzella, Shehab Mohamed, Francesco Petrella, Giulia Sedda, et al. Cancers, 2023 Background: Primary chest wall tumors comprise a heterogeneous group of neoplasms arising from soft tissues and bones. While surgical excision is the standard of care for benign tumors, the management of malignant tumors requires multimodal treatment. We conducted a predictive analysis of outcome, recurrence-free and overall survival. Methods: We retrospectively reviewed the clinical and pathological records of all patients treated in our center between 1998 and 2020. Results: 53 patients (15–85 years) were treated in our department. The average tumor diameter was 65 ± 35 mm (10–160 mm). Negative margins were obtained in 48 patients (90.6%), whereas in the remaining 5, R1 resection was accomplished. Median overall survival was 63,03 months (1–282 months). Overall survival was 90% at 1 year, 78% at 2 years, and 61% at 5 years. Our analysis identified tumor diameter, postoperative complications, and high grade of malignancy as factors that can influence prognosis. Conclusions: The treatment of primary chest wall tumors remains a very challenging process. Different histological types preclude definition of an unequivocal approach. Complete resection with healthy margins remains a definitive cornerstone in the treatment of these cancers as part of a more comprehensive approach.
Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study Monica Casiraghi, Francesco Petrella, Claudia Bardoni, Shehab Mohamed, Giulia Sedda, et al. Journal of Clinical Medicine, 2023 Introduction The suitability of adjuvant therapy (AT) in patients with stage IB non-small cell lung cancer (NSCLC) is still under debate considering the cost–benefit ratio between improvement in survival and side effects. We retrospectively evaluated survival and incidence of recurrence in radically resected stage IB NSCLC, to determine whether AT could significantly improve prognosis. Methods Between 1998 and 2020, 4692 consecutive patients underwent lobectomy and systematic lymphadenectomy for NSCLC. Two hundred nineteen patients were pathological T2aN0M0 (>3 and ≤4 cm) NSCLC 8th TNM. None received preoperative or AT. Overall survival (OS), cancer specific survival (CSS) and the cumulative incidence of relapse were plotted and log-rank or Gray’s tests were used to assess the difference in outcome between groups. Results The most frequent histology was adenocarcinoma (66.7%). Median OS was 146 months. The 5-, 10-, and 15-year OS rates were 79%, 60%, and 47%, whereas the 5-, 10-, and 15-year CSS were 88%, 85%, and 83%, respectively. OS was significantly related to age (p < 0.001) and cardiovascular comorbidities (p = 0.04), whereas number of LNs removed was an independent prognostic factor of CSS (p = 0.02). Cumulative incidence of relapse at 5-, 10-, and 15-year were 23%, 31%, and 32%, respectively, and significantly related to the number of LNs removed (p = 0.01). Patients with more than 20 LNs removed and clinical stage I had a significantly lower relapse (p = 0.02). Conclusions Excellent CSS, up to 83% at 15-year, and relatively low risk of recurrence for stage IB NSCLC (8th TNM) patients suggested that AT for those patients could be reserved only for very selected high-risk cases.
Serum proteomics profiling identifies a preliminary signature for the diagnosis of early-stage lung cancer Roberto Gasparri, Roberta Noberini, Alessandro Cuomo, Avinash Yadav, Davide Tricarico, et al. Proteomics Clinical Applications, 2023 PURPOSE Lung cancer is the most common cause of death from cancer worldwide, largely due to late diagnosis. Thus, there is an urgent need to develop new approaches to improve the detection of early-stage lung cancer, which would greatly improve patient survival. EXPERIMENTAL DESIGN The quantitative protein expression profiles of microvesicles isolated from the sera from 46 lung cancer patients and 41 high-risk non-cancer subjects were obtained using a mass spectrometry method based on a peptide library matching approach. RESULTS We identified 33 differentially expressed proteins that allow discriminating the two groups. We also built a machine learning model based on serum protein expression profiles that can correctly classify the majority of lung cancer cases and that highlighted a decrease in the levels of Arysulfatase A (ARSA) as the most discriminating factor found in tumors. CONCLUSIONS AND CLINICAL RELEVANCE Our study identified a preliminary, non-invasive protein signature able to discriminate with high specificity and selectivity early-stage lung cancer patients from high-risk healthy subjects. These results provide the basis for future validation studies for the development of a non-invasive diagnostic tool for lung cancer. This article is protected by copyright. All rights reserved.
Artificial Neural Networks in Lung Cancer Research: A Narrative Review Elena Prisciandaro, Giulia Sedda, Andrea Cara, Cristina Diotti, Lorenzo Spaggiari, et al. Journal of Clinical Medicine, 2023 Background: Artificial neural networks are statistical methods that mimic complex neural connections, simulating the learning dynamics of the human brain. They play a fundamental role in clinical decision-making, although their success depends on good integration with clinical protocols. When applied to lung cancer research, artificial neural networks do not aim to be biologically realistic, but rather to provide efficient models for nonlinear regression or classification. Methods: We conducted a comprehensive search of EMBASE (via Ovid), MEDLINE (via PubMed), Cochrane CENTRAL, and Google Scholar from April 2018 to December 2022, using a combination of keywords and related terms for “artificial neural network”, “lung cancer”, “non-small cell lung cancer”, “diagnosis”, and “treatment”. Results: Artificial neural networks have shown excellent aptitude in learning the relationships between the input/output mapping from a given dataset, without any prior information or assumptions about the statistical distribution of the data. They can simultaneously process numerous variables, managing complexity; hence, they have found broad application in tasks requiring attention. Conclusions: Lung cancer is the most common and lethal form of tumor, with limited diagnostic and treatment methods. The advances in tailored medicine have led to the development of novel tools for diagnosis and treatment. Artificial neural networks can provide valuable support for both basic research and clinical decision-making. Therefore, tight cooperation among surgeons, oncologists, and biostatisticians appears mandatory.
Learning Curve of Robotic Lobectomy for the Treatment of Lung Cancer: How Does It Impact on the Autonomic Nervous System of the Surgeon? Antonio Mazzella, Shehab Mohamed, Patrick Maisonneuve, Giulia Sedda, Andrea Cara, et al. Journal of Personalized Medicine, 2023 Objective: Our purpose is to define the learning curve for robot-assisted thoracoscopic surgery lobectomy by reporting the experience of a single surgeon. Material and methods: We progressively collected the data concerning the surgical performance of a single male thoracic surgeon, from the beginning of his robotic activity as first operator from January 2021 to June 2022. We evaluated several pre-, intra- and postoperative parameters concerning patients and intraoperative cardiovascular and respiratory outcomes of the surgeon, recorded during surgical interventions, in order to evaluate his cardiovascular stress. We used cumulative sum control charts (CUSUM) to analyze the learning curve. Results: A total of 72 lung lobectomies were performed by a single surgeon in this period. Analyzing the CUSUM of several parameters, the inflection point identifying the transition beyond the surgeon learning phase was reached at cases 28, 22, 27 and 33 when considering operating time, mean heart rate, max heart rate and mean respiratory rate, respectively. Conclusions: The learning curve for robotic lobectomy seems to be safe and feasible with a correct robotic training program. The analysis of a single surgeon from the beginning of his robotic activity demonstrates that confidence, competence, dexterity and security are achieved after about 20–30 procedures, without compromising efficiency and oncological radicality.
Surgical management of superior sulcus tumors: A twenty-year experience of an oncological high volume referral centre Luca Bertolaccini, Monica Casiraghi, Domenico Galetta, Francesco Petrella, Antonio Mazzella, et al. Frontiers in Oncology, 2023 ObjectivesSuperior sulcus tumour, which affects the lung’s apex, is an uncommon subtype of non-small cell lung cancer (NSCLC). The current study examined the clinical characteristics and management of superior sulcus NSCLC patients in a high-volume referral oncological centre over 22 years.MethodsRetrospective review of 100 surgeries with curative intent for superior sulcus NSCLC over 22 years (July 1998 – December 2020). The surgical approach was defined according to the lesion site and the anatomy of the thoracic inlet. Survival curves, including non-cancer-related deaths, were drawn using the Kaplan-Meier methods, and the log-rank test was used to evaluate differences in survival across groups of patients. Cox proportional hazards regression was used to assess the association between selected clinical and pathologic characteristics on OS.Results54 patients received induction treatments. The surgical approach was anterior thoracotomy in 53 patients, Paulson incision in 30, and a combined in 8. The median postoperative length of stay was 11 days (range: 5 – 27 days). Overall 90-day mortality was 6.93%. The median OS was 24.3 months. After a median follow-up of 3 years, 5-year and 10-year OS rates were 33.9% and 26.4%, respectively. A significantly lower 5-year OS was observed in patients with the nodal disease (46.6% in pN0 vs 13.2% in pN+; p = 0.024), without preoperative treatments (41.0% in patients without preoperative treatments versus 17.4%; p = 0.09) and anteriorly located tumour (anterior vs posterior: 17.4% vs 49.1%; p = 0.032). Cox proportional hazards regression showed better survival in the pT1 stage (HR = 4.6; 95% CI: 1.9 – 11.2; p = 0.00076) and in R0 (HR = 4.2; 95% CI: 1.4 – 12.5; p = 0.010).ConclusionsSuperior sulcus tumours still represent a life-threatening condition that, while curable in a significant proportion of cases, requires complex procedures with high surgical risks and a multimodality treatment setting. An optimal surgical approach should be planned to maximise resection completeness and survival. Other factors affecting survival are related to tumour staging, emphasising the importance of a meticulous preoperative workup and candidate selection to identify those expected to benefit from a survival benefit.
Real-world survival outcomes of wedge resection versus lobectomy for cT1a/b cN0 cM0 non-small cell lung cancer: a single center retrospective analysis Luca Bertolaccini, Andrea Cara, Matteo Chiari, Cristina Diotti, Nimrod Glick, et al. Frontiers in Oncology, 2023 BackgroundJCOG0802/WJOG4607L showed benefits in overall survival (OS) of segmentectomy. CALGB 140503 confirmed that sublobar resection was not inferior to lobectomy concerning recurrence-free survival (RFS) but did not provide specific OS and RFS according to the techniques of sublobar resections. Hence, we retrospectively analyze the survival differences between wedge resection and lobectomies for stage IA lung cancer.MethodsWe reviewed the clinical records of patients with clinical stage IA NSCLC over 20 years. The inclusion criteria were: preoperative staging with CT scan and whole body CT/PET; tumor size &lt;20 mm; wedge resections or lobectomies with or without lymph node dissection; NSCLC as the only primary tumor during the follow-up period. We excluded: multiple invasive lung cancer; positive resection margin; preoperative evidence of nodal disease; distant metastasis at presentation; follow-up time &lt;5 years. The reverse Kaplan – Meier method estimated the median OS and PFS and compared them by the log-rank test. The stratified backward stepwise Cox regression model was employed for multivariable survival analyses.Results539 patients were identified: 476 (88.3%) lobectomies and 63 (11.7%) wedge resections. The median OS time for the whole cohort was 189.7 months (range: 173.7 – 213.9 months). The 5-year wedge resection and lobectomy OS were 82.2% and 87.0%. The 5-year RFS of wedge resection and lobectomy were 17.8% and 28.9%. The log-rank test showed no significant differences (p = 0.39) between wedge resections and lobectomies regarding OS and RFS (p = 0.23).ConclusionsLobectomy and wedge resection are equivalent oncologic treatments for individuals with cN0/cM0 stage IA NSCLC &lt;20 mm. Validating the current findings requires a prospective, randomized comparison between wedge resection and standard lobectomy to establish the prognostic significance of wedge resection.
Safety and Efficacy of Single-Stage Synchronous Bilateral VATS Talc Poudrage for Malignant Pleural Effusion A Mazzella, S Degiovanni, E Mariani, G Cerretani, L Bertolaccini, ... Cancers 18 (11), 1676 , 2026 2026
Recurrent Malignant Pericardial Effusion Management: The Pericardio-Peritoneal Window A Mazzella, G Caffarena, C Bardoni, G Nicolosi, P Maisonneuve, ... Journal of Clinical Medicine 15 (1), 83 , 2025 2025 Citations: 1
EMG-based visual biofeedback applied to upper limb motor tasks in virtual environment G Sedda, E Ariu, R Melis, J Vacca, ME Lai, G Pili, M Caruso, D Balta, ... Gait & Posture 122, 109944.49 , 2025 2025
Automatic detection of motor stereotypies in Rett Syndrome using wearable sensors ME Lai, F Pes, J Vacca, M Semino, M Perina, E Riccio, L Zocca, G Sedda, ... Gait & Posture 122, 109944.54 , 2025 2025
Nonlinear error augmentation applied to upper limb movements enhances motor learning * G Sedda, G Olla, D Pani 2025 47th Annual International Conference of the IEEE Engineering in … , 2025 2025
A user-friendly wearable telerehabilitation system based on neuromotor training for mild post-stroke patients: the DoMoMEA system A Zedda, M Caruso, S Bertuletti, G Baldazzi, G Sedda, A Spanu, D Riboni, ... IEEE Access , 2025 2025 Citations: 2
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in … L Bravo, JFF Simões, VR Cardoso, A Adisa, ML Aguilera, A Arnaud, ... The Lancet Digital Health 6 (7), e507-e519 , 2024 2024 Citations: 9
MYRTUS: Multi-layer 360 dYnamic orchestration and interopeRable design environmenT for compute-continUum Systems F Palumbo, MK Zedda, T Fanni, A Bagnato, L Castello, J Castrillon, ... Proceedings of the 21st ACM International Conference on Computing Frontiers … , 2024 2024 Citations: 13
Facilitation in Pattern Motion Perception of Self-operated Stimuli Explained by Adaptive Contrast Normalization F Missoni, F Peveri, A Canessa, G Sedda, V Sanguineti, SP Sabatini 2024
Integrating artificial intelligence tool in multidisciplinary tumor board for predicting complications after lung cancer surgery L Bertolaccini, E Prisciandaro, C Uslenghi, G Maffeis, G Sedda, ... European Respiratory Journal 62 (suppl 67) , 2023 2023 Citations: 2
Real-world survival outcomes of wedge resection versus lobectomy for cT1a/b cN0 cM0 non-small cell lung cancer: a single center retrospective analysis L Bertolaccini, A Cara, M Chiari, C Diotti, N Glick, S Mohamed, C Uslenghi, ... Frontiers in Oncology 13, 1226429 , 2023 2023 Citations: 13
Specific motor learning induced by space-variant visual feedback distortion of the hand position G Sedda, G Olla, D Pani Journal of Vision 23 (9), 5443-5443 , 2023 2023
Diagnostic performance and cell count of EBUS–TBNA needle gauges: a prospective trial J Guarize, C Diotti, M Casiraghi, S Donghi, C Di Tonno, P Mancuso, ... Journal of Clinical Medicine 12 (12), 4033 , 2023 2023 Citations: 9
The role of surgery in primary chest wall tumors: over 20 years’ experience in resection and reconstruction G Lo Iacono, A Mazzella, S Mohamed, F Petrella, G Sedda, M Casiraghi, ... Cancers 15 (7), 2153 , 2023 2023 Citations: 16
92P Predictors, surrogate and patient-reported outcomes in neoadjuvant immunotherapy for lung cancer: A single-center retrospective study L Bertolaccini, S Mohamed, D Galetta, F Petrella, M Casiraghi, C Diotti, ... Journal of Thoracic Oncology 18 (4), S94-S95 , 2023 2023 Citations: 1
Surgically treated pT2aN0M0 (stage IB) non-small cell lung cancer: a 20-Year single-center retrospective study M Casiraghi, F Petrella, C Bardoni, S Mohamed, G Sedda, J Guarize, ... Journal of Clinical Medicine 12 (5), 2081 , 2023 2023 Citations: 5
Serum proteomics profiling identifies a preliminary signature for the diagnosis of early‐stage lung cancer R Gasparri, R Noberini, A Cuomo, A Yadav, D Tricarico, C Salvetto, ... PROTEOMICS–Clinical Applications 17 (2), 2200093 , 2023 2023 Citations: 8
Artificial neural networks in lung cancer research: a narrative review E Prisciandaro, G Sedda, A Cara, C Diotti, L Spaggiari, L Bertolaccini Journal of clinical medicine 12 (3), 880 , 2023 2023 Citations: 40
Learning curve of robotic lobectomy for the treatment of lung cancer: how does it impact on the autonomic nervous system of the surgeon? A Mazzella, S Mohamed, P Maisonneuve, G Sedda, A Cara, M Casiraghi, ... Journal of Personalized Medicine 13 (2), 193 , 2023 2023 Citations: 15
Surgical management of superior sulcus tumors: A twenty-year experience of an oncological high volume referral centre L Bertolaccini, M Casiraghi, D Galetta, F Petrella, A Mazzella, G Lo Iacono, ... Frontiers in Oncology 12, 1080765 , 2023 2023 Citations: 3
MOST CITED SCHOLAR PUBLICATIONS
Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study MI GONZALEZ Anaesthesia , 2021 2021 Citations: 677
Volatile signature for the early diagnosis of lung cancer R Gasparri, M Santonico, C Valentini, G Sedda, A Borri, F Petrella, ... Journal of breath research 10 (1), 016007 , 2016 2016 Citations: 177
SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study C COVIDSurg, C GlobalSurg Anaesthesia: Peri-operative medicine, critical care and pain , 2022 2022 Citations: 133
A review of exhaled breath: a key role in lung cancer diagnosis D Marzorati, L Mainardi, G Sedda, R Gasparri, L Spaggiari, P Cerveri Journal of breath research 13 (3), 034001 , 2019 2019 Citations: 107
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study GS Collaborative, COVIDSurg Collaborative The British journal of surgery 108 (9), 1056 , 2021 2021 Citations: 71
Diagnostic biomarkers for lung cancer prevention R Gasparri, R Romano, G Sedda, A Borri, F Petrella, D Galetta, ... Journal of Breath Research 12 (2), 027111 , 2018 2018 Citations: 57
Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries JC Glasbey, TEF Abbott, A Ademuyiwa, A Adisa, E AlAmeer, S Alshryda, ... The Lancet 400 (10363), 1607-1617 , 2022 2022 Citations: 56
Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 76 (11), 1454-1464 , 2021 2021 Citations: 51
Lung cancer surgery in oligometastatic patients: outcome and survival M Casiraghi, L Bertolaccini, G Sedda, F Petrella, D Galetta, J Guarize, ... European Journal of Cardio-Thoracic Surgery 57 (6), 1173-1180 , 2020 2020 Citations: 50
Volatolomic urinary profile analysis for diagnosis of the early stage of lung cancer R Gasparri, R Capuano, A Guaglio, V Caminiti, F Canini, A Catini, ... Journal of Breath Research 16 (4), 046008 , 2022 2022 Citations: 43
Artificial neural networks in lung cancer research: a narrative review E Prisciandaro, G Sedda, A Cara, C Diotti, L Spaggiari, L Bertolaccini Journal of clinical medicine 12 (3), 880 , 2023 2023 Citations: 40
MOS sensors array for the discrimination of lung cancer and at-risk subjects with exhaled breath analysis D Marzorati, L Mainardi, G Sedda, R Gasparri, L Spaggiari, P Cerveri Chemosensors 9 (8), 209 , 2021 2021 Citations: 37
A metal oxide gas sensors array for lung cancer diagnosis through exhaled breath analysis D Marzorati, L Mainardi, G Sedda, R Gasparri, L Spaggiari, P Cerveri 2019 41st Annual International Conference of the IEEE Engineering in … , 2019 2019 Citations: 37
Surgery for small cell lung cancer: When and how M Casiraghi, G Sedda, E Del Signore, G Piperno, P Maisonneuve, ... Lung Cancer 152, 71-77 , 2021 2021 Citations: 36
A brief report on survival after robotic lobectomy for early-stage lung cancer L Spaggiari, G Sedda, P Maisonneuve, A Tessitore, M Casiraghi, ... Journal of Thoracic Oncology 14 (12), 2176-2180 , 2019 2019 Citations: 33
Two-step investigation of lung cancer detection by sniffer dogs SM Mazzola, F Pirrone, G Sedda, R Gasparri, R Romano, L Spaggiari, ... Journal of Breath Research 14 (2), 026011 , 2020 2020 Citations: 32
Non-intubated thoracoscopic lobectomies for lung cancer: an exploratory systematic review and meta-analysis E Prisciandaro, L Bertolaccini, G Sedda, L Spaggiari Interactive CardioVascular and Thoracic Surgery 31 (4), 499-506 , 2020 2020 Citations: 31
Clinical application of mass spectrometry‐based proteomics in lung cancer early diagnosis R Gasparri, G Sedda, R Noberini, T Bonaldi, L Spaggiari PROTEOMICS–Clinical Applications 14 (5), 1900138 , 2020 2020 Citations: 23
The electronic nose’s emerging role in respiratory medicine R Gasparri, G Sedda, L Spaggiari Sensors 18 (9), 3029 , 2018 2018 Citations: 23
Postoperative outcomes of robotic-assisted lobectomy in obese patients with non-small-cell lung cancer M Casiraghi, G Sedda, C Diotti, AV Mariolo, D Galetta, A Tessitore, ... Interactive CardioVascular and Thoracic Surgery 30 (3), 359-365 , 2020 2020 Citations: 22
